Dupilumab reduces mucus plugging and improves lung function in patients with moderate-to-severe type 2 asthma.

Most patients with chronic rhinosinusitis with nasal polyps no longer used oral corticosteroids after using dupilumab, ...

A systematic review reports that monoclonal antibodies and JAK inhibitors can be effective in the treatment and clearance of ...

Dupilumab reduces mucus plug scores and improves lung function in patients with moderate-to-severe asthma and high baseline ...

An anti-inflammation injectable drug called dupilumab can reduce mucus buildup and improve breathing among asthma patients, a ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years ...

Abrocinitib was slightly more effective than dupilumab in treating atopic dermatitis, both in White patients and in patients with skin of color.

Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions First and only therapy to specifically target the ...

Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...

Regeneron and Sanofi’s Dupixent trial shows major improvement in allergic fungal rhinosinusitis symptoms in patients 6+. Read ...